Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Equity Average (2016 - 2025)

Historic Equity Average for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $253.5 million.

  • Collegium Pharmaceutical's Equity Average rose 1245.44% to $253.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $253.5 million, marking a year-over-year increase of 1245.44%. This contributed to the annual value of $212.1 million for FY2024, which is 871.19% up from last year.
  • Collegium Pharmaceutical's Equity Average amounted to $253.5 million in Q3 2025, which was up 1245.44% from $233.3 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Equity Average peaked at $253.5 million during Q3 2025, and registered a low of $178.0 million during Q1 2021.
  • In the last 5 years, Collegium Pharmaceutical's Equity Average had a median value of $208.8 million in 2024 and averaged $211.4 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Equity Average skyrocketed by 5583.1% in 2021, and later plummeted by 2169.03% in 2022.
  • Over the past 5 years, Collegium Pharmaceutical's Equity Average (Quarter) stood at $227.0 million in 2021, then decreased by 13.65% to $196.0 million in 2022, then decreased by 4.52% to $187.2 million in 2023, then grew by 23.73% to $231.6 million in 2024, then rose by 9.48% to $253.5 million in 2025.
  • Its Equity Average was $253.5 million in Q3 2025, compared to $233.3 million in Q2 2025 and $231.6 million in Q1 2025.